Trial Profile
A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment with Epirubicin, Cisplatin, and Capecitabine (ECX) plus AMG 102
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Jul 2019
Price :
$35
*
At a glance
- Drugs Rilotumumab (Primary) ; Capecitabine; Cisplatin; Epirubicin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2013 Planned End Date changed from 1 Feb 2013 to 1 Jun 2013, as reported by ClinicalTrials.gov.